Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Investors may wish to note that the Executive Vice President of Discovery of Repare Therapeutics Inc., Cameron Black, recently netted US$66k from selling stock, receiving an average price of US$26.49. On the bright side, that's just a small sale and only reduced their holding by 7.4%.

View our latest analysis for Repare Therapeutics

Repare Therapeutics Insider Transactions Over The Last Year

The Executive VP and Head of Business & Corporate Development, Kim Seth, made the biggest insider sale in the last 12 months. That single transaction was for US$1.4m worth of shares at a price of US$35.50 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$28.18. So it is hard to draw any strong conclusion from it.

Over the last year, we can see that insiders have bought 30.55k shares worth US$611k. But insiders sold 94.55k shares worth US$3.2m. All up, insiders sold more shares in Repare Therapeutics than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Repare Therapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 1.1% of Repare Therapeutics shares, worth about US$11m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Repare Therapeutics Insiders?

Insiders sold Repare Therapeutics shares recently, but they didn't buy any. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Repare Therapeutics has 5 warning signs (2 don't sit too well with us!) that deserve your attention before going any further with your analysis.

But note: Repare Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you decide to trade Repare Therapeutics, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.